Published in final edited form as:

Curr Opin Ophthalmol. 2017 May ; 28(3): 252–259. doi:10.1097/ICU.0000000000000359.

CRISPR Applications in Ophthalmologic Genome Surgery

Thiago Cabral, MD^{1,2,3,4,*}, James E DiCarlo, PhD^{1,2,*}, Sally Justus, BA^{1,2}, Jesse D Sengillo, BS^{1,2,5}, Yu Xu, MD^{1,2,6}, and Stephen H Tsang, MD, PhD^{1,2,7,§}

¹Jonas Children's Vision Care, and Bernard & Shirlee Brown Glaucoma Laboratory, Department of Ophthalmology, Columbia University Medical Center, New York, NY, USA

²Edward S Harkness Eye Institute, New York-Presbyterian Hospital, New York, NY, USA

³Department of Ophthalmology, Federal University of Espirito Santo, Vitoria, Brazil

⁴Department of Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil

⁵State University of New York Downstate Medical Center, Brooklyn, NY, USA

⁶Department of Ophthalmology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University

⁷Department of Pathology & Cell Biology, Institute of Human Nutrition, College of Physicians and Surgeons, Columbia University, New York, NY, USA

Abstract

Purpose of review—This review seeks to summarize and discuss the application of CRISPR-Cas systems for genome editing, also called “genome surgery,” in the field of ophthalmology.

Recent findings—Precision medicine is an emerging approach for disease treatment and prevention that takes into account the variability of an individual's genetic sequence. Various groups have used CRISPR-Cas genome editing to make significant progress in mammalian preclinical models of eye disease, the basic science of eye development in zebrafish, the *in vivo* modification of ocular tissue, as well as the correction of stem cells with therapeutic applications. Additionally, investigators have creatively used the targeted mutagenic potential of CRISPR-Cas systems to target pathogenic alleles in vitro.

Summary—Over the past year, CRISPR-Cas genome editing has been used to correct pathogenic mutations in vivo as well as in transplantable stem cells. While off-target mutagenesis remains a concern, improvement in CRISPR-Cas technology and careful screening for undesired mutations will likely lead to clinical eye therapeutics employing CRISPR-Cas systems in the near future.

Keywords

CRISPR-Cas; iPSCs; ESCs; AAV; Precision Medicine

§Address Correspondence: Stephen H Tsang, Harkness Eye Institute, Barbara & Donald Jonas Stem Cell & Regenerative Medicine Laboratory, and Bernard & Shirlee Brown Glaucoma Laboratory, Department of Ophthalmology, Columbia University Medical Center & the Edward S Harkness Eye Institute, Columbia University Medical Center. 635 West 165th Street, 5th floor, New York, NY 10032, Phone: (212) 342-1189 / Fax: 212-305-4987 / sht2@columbia.edu.

*These authors contributed equally to the manuscript.

Conflicts of interest

J.E.D. is an author of a patent application filed on CRISPR/Cas9 application for genome engineering in eukaryotes (PCT/US2014/045691)

Introduction

Inherited genetic disorders of the eye result in severe functional deficits in patients, and to date, many of these disorders have been intractable to precision-based therapies. [1,2] Since the first efforts to sequence the human genome, scientists and physicians have aimed to modify pathogenic genomic loci to alleviate disease burden. [3–5] Recently, with the advent of technologies for direct DNA modification, practicing precision genome surgery in ophthalmology is now closer to becoming a reality. Originally derived from the immune system of bacteria and archaea, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) -associated systems (Cas) have become repurposed for DNA manipulation in biomedicine. [6] This review seeks to highlight the use of CRISPR-Cas systems in ophthalmology, particularly over the past year.

CRISPR-Cas genome engineering

Targeting double-strand breaks (DSBs) to the desired genomic loci has become a mainstay for the modification of eukaryotic systems. [7] These DSBs can be repaired either by homologous recombination using a sequence with homology to the sequence flanking the cut site, a strategy known as homology-directed repair (HDR), or by non-homologous end joining (NHEJ), an error-prone process that does not rely on a template and can result in generation of the original sequence or a mutated version, often containing insertions and deletions (INDELs).[8] Over the past few decades, meganucleases, zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) have been the dominant tool for the introduction of DSBs in cells.[9] While these tools can be used to generate precise DSBs, their engineering can be laborious and time intensive due to protein engineering considerations, among other factors.[6] In 2012 the mechanistic actions of the reprogrammable endonucleases from the CRISPR-Cas system of *Streptococcus pyogenes* were first elucidated in detail, and since their first implementation in human cells, the repurposing of this system for genome surgery has skyrocketed.[6,10–12]

Due to the ease of re-engineering CRISPR-Cas systems for diverse targets, this system has become popular for genome surgery in a large variety of organisms.[13–20] CRISPR-Cas genome editing from the type II CRISPR system of *Streptococcus pyogenes* relies on the RNA-guided endonuclease, Cas9 (SpCas9), and two RNA molecules, a CRISPR RNA (crRNA) and a trans-activating RNA (tracrRNA), which associate and complex with Cas9 to guide cleavage of DNA sequences based on homology between the crRNA and target DNA strand.[10,21,22] A chimeric molecule of the crRNA and tracrRNA was created and subsequently dubbed ‘single guide RNA’ (sgRNA), which was demonstrated to be as effective as the original system.[10] The sgRNA contains a twenty base pair region that binds to the homologous DNA strand. Cas9 associates with the DNA and generates a blunt cut three base pairs upstream of the protospacer adjacent motif (PAM), a three-nucleotide sequence required for Cas9 sequence association (canonically an NGG sequence).[10,23–25] While other endonucleases like the Cas9 derived from *Streptococcus pyogenes* have been discovered and optimized for gene editing purposes, SpCas9 has been utilized the most since its introduction. [6]

SpCas9 has been further modified to attenuate its cutting ability to that of a nickase (SpCas9D10A), wherein the enzyme is only able to induce a single-stranded break rather than a DSB.[26,27] SpCas9 has also been modified to completely remove its nuclease activity (termed dCas9 for ‘catalytically dead Cas9’) to allow for activator and repressor protein fusions.[26,27] Because of the versatile applications of SpCas9 to edit, activate, repress and even epigenetically modify DNA *in vivo*, CRISPR-Cas systems have become essential tools in biotechnology [26,28–32]. (Figure 1 A–E) Recently, Komor et al. developed dCas9-deaminase and Cas9-nickase-deaminase fusions capable of targeting cytidine to uridine transitions and allowing for directed mutagenesis without introducing a DSB [33]. (Figure 1 F)

Off-target binding of Cas enzymes are important considerations especially when the generation of precise modifications is essential, as it is in clinical situations.[34] While there are several softwares available to predict off-target binding of RNA-guided endonucleases using sgRNA target sequences and the host genome, a recent experimental study by Tsai et al. showed that there is variability in predicted and experimentally verified off-target binding sites.[35] This suggests that examining off-target modifications via CRISPR-Cas in a clinical setting is crucial.

CRISPR-Cas genome editing in Mammalian Preclinical Models of the Eye

The ease, reduced cost, and rapid speed of generating novel RNA-guided endonucleases have revolutionized the generation of animal models.[15,36] Recently, Wu et al. used CRISPR-Cas genome editing to untangle the effects of two potentially pathogenic genetic differences in “rodless” (*rd1*, *Pde6b^{rd1}/Pde6b^{rd1}*) mice, an important preclinical model system for retinitis pigmentosa (RP).[37] These *rd1* mice exhibit premature rod neuronal death believed to be a result of mutations in the *Pde6b* gene, which regulates intracellular cGMP levels.[38,39] The *rd1* mouse genome contains a nonsense mutation (Y347X) in the *Pde6b* gene as well as an insertion of a murine leukemia virus (*Xmv-28*) into intron 1 of *Pde6b*. It was unclear if the *Xmv-28* insertion contributed to the *rd1* phenotype, so the group used CRISPR-Cas genome editing, utilizing a single-stranded oligonucleotide as the donor, to generate mice with a repaired Y347X nonsense mutation in *Pde6b^{rd1}/Pde6b^{rd1}* homozygous mice, the background still containing the *Xmv-28* insertion. Using funduscopy, electroretinography, optical coherence tomography and hematoxylin and eosin staining, the group showed that the wild type phenotype could be restored by repairing the Y347X nonsense mutation alone, suggesting that the *Xmv-28* viral insertion is benign.

CRISPR-Cas genome editing has also been used to generate mosaic tissue models of disease. The *KCNJ13* gene encodes the apically localized, RPE-specific potassium channel subunit Kir7.1. Mutations in this channel are associated with Leber Congenital Amaurosis, and in mice, homozygous null mutants of *KCNJ13* result in postnatal lethality.[40] Classically, scientists have employed Cre-lox systems to knock out essential genes in adult multicellular organisms and study the resulting phenotype. Briefly, the Cre-lox system enables site-specific recombination at genes of interest that have been modified to contain loxP sites flanking their 5’ and 3’ ends, and it concurrently requires the introduction of a transgenic Cre recombinase. Genes can then be excised via endogenous or exogenous

induction of the recombinase.[41] However, generation of Cre-lox systems in mice can take at least one year. To avoid this delay, Zhong et al. took advantage of the heterogeneity of the mutations generated by NHEJ.[40,42] After injection of sgRNA and SpCas9 mRNA into mouse zygotes, the developed animals exhibited tissue mosaicism with respect to the *Kcnj13* locus based on tail genotyping, which is indicative of mosaicism within the retina as well. This model allowed the investigators to study the effects of a loss of function of KCNJ13 at a tissue level, which they concluded correlated with loss of photoreceptors and rhodopsin mislocalization. By employing a model that utilized NHEJ-induced mosaicism instead of conventional knockout via a Cre-loxP system, the generation of CRISPR mice was much more rapid, and diverse genotypes could be examined simultaneously.

Conversely, CRISPR-Cas genome editing can be used to make precise, single base pair changes. To assess the effects of the rs2279744 single nucleotide polymorphism (SNP) implicated in retinal detachment and carcinogenesis in proliferative vitreoretinopathy, Duan et al. exploited CRISPR genome editing. They induced the SNP, a T309G mutation in *Mdm2* (murine double minute 2, an implicated inhibitory regulation of p53), into human primary retinal pigment epithelial (hPRPE) cells *in vitro*.[43] The SNP was imparted using AAV-delivered *Streptomyces pyogenes* nickase SpCas9D10A, which was guided by two sgRNA constructs that flanked the *Mdm2* locus (these guide RNAs were previously tested for activity using WT SpCas9). The group found that while 42.51% of the cells were modified, only 10% of the modified cells were homozygous for the T309G mutation. The group then examined hPRPE responsiveness to apoptotic factors in rabbit vitreous and found that *Mdm2* T309G hPRPE cells were less responsive to apoptosis and more proliferative in rabbit vitreous, further implicating the allele in promoting proliferation in vitreous environments. Using CRISPR-Cas systems to generate human SNPs *in vivo* is a powerful method for screening pathogenicity, a platform that will be used increasingly more with the popularization of personalized medicine paradigms.[44,45]

Additionally, other groups have used CRISPR-Cas systems to knockout genes in parallel with siRNA (short interfering RNA), which are short (~20–30 nucleotides), non-coding RNA sequences that can be designed to repress the expression of genes of interest. [46,47] Priglinger *et al.* used CRISPR-Cas genome editing to study key processes involved in the epithelial-to-mesenchymal transition of RPE.[48] This transition is a crucial step in proliferative vitreoretinopathy, and understanding its mechanism is essential for developing therapeutics.[49] The investigators found that CRISPR-Cas-induced knockout of β 1,6 N-acetylglucosaminyltransferase V (*MGAT5*) in human RPE cells, along with siRNA knockdown in a separate experiment, decreased the binding of galectin-3 (Gal-3) to glycans on RPE cells *in vitro*. Gal-3 is an important modulator of RPE growth *in vivo*, and this binding modulation provided by *MGAT5* makes it an interesting target for therapy.[48] This study shows the use of CRISPR-Cas genome surgery as a parallel tool to classic techniques such as siRNA knockdown.

Advances in ocular genetics using CRISPR-Cas genome editing in zebrafish

In addition to mouse and human tissue, zebrafish represent an attractive model for human disease due to their rapid lifecycle ease of manipulation, and highly orthologous correlation with human genes.[50] CRISPR-Cas genome editing has previously been applied to zebrafish.[20] Yin *et al.* used retina tissue-specific delivery (injection and electroporation) of sgRNA targeted to the zebrafish retinal regeneration gene *Asc11a* in a strain background constitutively expressing SpCas9.[51] Targeting *Asc11a* for cleavage resulted in a reduction of retinal proliferation compared with controls, as expected.[52] This study shows that spatial and temporal delivery and expression of CRISPR components are a powerful way to regulate gene activity in zebrafish, especially when targeting small cell populations in specific tissues such as the eye.

Zebrafish are a powerful model for studying development. Taylor et al. induced mutations in the gene *NeuroD*, a potential player in retinal regeneration in zebrafish, via CRISPR-Cas genome editing.[53] The group targeted *NeuroD* using sgRNA and SpCas9 to induce deleterious mutations in zebrafish embryos, and they also suppressed the gene using morpholinos oligonucleotides to provide a point of comparison. Their data suggested that *NeuroD* is a regulator of Notch signaling, confirming its important role in photoreceptor regeneration.[53] By using both classical genetic techniques such as morpholino knockdown as well as CRISPR-Cas genome editing, the findings of this study were strengthened by the rigorous experimental design.

Targeting Dominant-Negative Alleles using CRISPR-Cas *in vivo*

Mismatch in the 20 base pair target sequences of the sgRNA can have severe effects on SpCas9 cleavage, especially if the mismatch occurs in the 12 base pair sequence closest to the PAM (seed sequence).[54] Additionally, alterations in the PAM sequence from canonically acceptable sequences can ablate cutting ability. Courtney *et al.* used this characteristic of sgRNA-SpCas9 complexes to specifically target the C395T mutation in the *KRT12* gene, a dominant-negative allele for Meesmann epithelial corneal dysplasia (MECD) in heterozygous patients.[55] This particular SNP results in a novel PAM sequence which the investigators targeted with a sgRNA. Their goal was to either induce inactivating mutations (nonsense or frameshift mutations) via non-homologous end joining repair or correct the allele using the wild type sequence.

After validation of sgRNA activity *in vitro*, the investigators used intrastromal injection of sgRNA and SpCas9-GFP plasmids to target the SNP in a humanized heterozygous mouse model of MECD. The *Krt12* locus was then amplified from the treated mice, and of the thirteen sequences that were analyzed, five contained NHEJ-derived mutations, four of which resulted in early termination of the pathogenic allele. This study illuminates the potential of CRISPR-Cas genome editing to not only insert beneficial alleles, but also to inactivate deleterious ones.

Bakondi *et al.* have applied a similar approach to ablate the autosomal dominant *Rho*^{S334} allele in a retinitis pigmentosa rat model, a mutant allele that results in misprocessing of the RHO protein and apoptotic death of photoreceptors. The *Rho*^{S334} allele contains a novel PAM sequence which the investigators targeted with a sgRNA that was first tested *in vitro* for targeting efficacy. sgRNA and SpCas9 plasmids were introduced via subretinal injection and electroporated to stimulate uptake into photoreceptors. Two rats in the study showed an INDEL frequency of 33% and 36% as a result of NHEJ in the *Rho*^{S334} locus. In the CRISPR-Cas ablated *Rho*^{S334} rats, the authors reported a 53% increase in visual acuity as assessed by the optokinetic behavioral response and a 35% increase in visual acuity using untreated contralateral eyes as controls within individuals. Lastly, the investigators reported a nine-fold increase in nuclei density in photoreceptors at P33.[56] These beneficial effects, both functionally and histologically, of pathogenic allele ablation further support the use of CRISPR-Cas for therapies that require the removal of dominant-negative alleles. (Figure 2 A and B)

***In vivo* delivery of CRISPR-Cas systems**

Direct delivery of CRISPR-Cas components to retinal tissue for genome surgery in patients is an important goal that is still being studied and pursued. To this end, Hung *et al.* examined the efficacy of dual adeno-associated viral (AAV) delivery of SpCas9 and validated Yellow Fluorescent Protein (YFP)-targeted guide RNA components were introduced into *Thy1::YFP* adult transgenic mice via intravitreal injections.[57] These mice have a *YFP* gene inserted into the *Thy1* locus, and CRISPR-Cas induced cleavage and the error-prone NHEJ repair would result in a decrease in functional YFP expression. Post-delivery, the group found an 84% reduction in YFP expression in cells that contained YFP-sgRNA constructs as compared to a non-cutting sgRNA control. Using whole retinal mounts, the group could determine the efficacy of knockout across retinal layers, with AAV2 transduction being the greatest in retinal ganglion cells (RGCs). Without selection for sgRNA-containing cells, there was a 50% reduction in YFP expression in RGCs. Using electroretinography, no significant retinal changes could be observed 5 weeks post-transduction, indicating a lack of toxicity to CRISPR components. Recently, delivery of CRISPR-Cas components *in vivo* and modification of endogenous loci has been successful with varying degrees of efficacy. [58–63] Similarly, AAV delivery of therapeutic DNA to eye tissue has been increasingly promising due to tropism preferences of AAV and the immune status of the eye.[64–66] This study shows the potential of *in vivo* genome engineering in adult animal retina, a technique that will likely become more translationally relevant in the near future.

Modification of Stem Cells using CRISPR-Cas genome editing

Patient-specific induced pluripotent stem cells (iPSCs) may be an ideal source of autologous cells to ameliorate many diseases. [67–71] Bassuk et al. showed that CRISPR-Cas genome editing could be used to correct a novel mutation in the retinitis pigmentosa GTPase regulator (RPGR) locus (c.3070G > T, pGlu1024X which results in a relatively severe X-linked RP phenotype.[72] Using skin-punch biopsy, cells were collected then transformed into iPSCs, which have the potential to be differentiated into retinal cells. Due to the high

GC content and repetition in the locus, 21 sgRNA constructs were tested *in vitro*, and one was chosen based on specificity and efficacy (sgRNA g58). Patient-derived iPSCs were modified via transfection of SpCas9, sgRNA g58, and a WT RPGR anti-sense, single-stranded oligonucleotide donor, resulting in 13% of the cells containing the corrected allele. While not completed in this study, correctly differentiated iPSCs could theoretically be autologously transplanted back into patients.

Human embryonic stem cells (hESCs) also serve as a potential source of cells for allotransplantation, in addition to representing important tools for studying human development. Sluch *et al.* sought to ease the isolation of hESC-derived RGCs by using CRISPR-Cas genome editing to link mCherry, a red fluorescent protein that enables genome engineering to be visualized (among other purposes), to the BRN3B gene (an important marker for RGCs) using a P2A self-cleaving peptide linker in h7 hESCs. [73,74] The group first targeted the stop codon of BRN3B by electroporation of sgRNA with spCas9 plasmids and an mCherry gene containing a 5' P2A linker with homology arms to the cut locus. The cell line was then differentiated to RGCs and then sorted by flow cytometry using the mCherry reporter. The mCherry-enriched cells were then analyzed for markers of RGCs via real time polymerase chain reaction (qPCR), used to quantitatively measure DNA amplification over time, and fluorescence staining. Ultrastructural and electrophysiological properties, assayed by transmission electron microscopy and whole-cell current clamp, respectively, further confirmed RGCs phenotype. The investigators also examined the frequency of off-target mutation at predicted sites and were unable to find off-target mutagenesis. In summary, tagging of a marker of RGC lineage using CRISPR-Cas editing allowed for rapid isolation of RGCs derived from hESCs.

Conclusion

CRISPR-Cas-derived tools will continue to revolutionize modern biology. In ophthalmology, these tools allow for exquisite manipulation of the genomic content in ocular cells. Due to the power of precision medicine, it is likely that the pace at which both mammalian and non-mammalian models for eye disease are used to test other therapeutics in patient-specific backgrounds will increase greatly, finally allowing for treatment plans that are tailored to each patient and genetically informed. As patient safety is at the utmost importance, vigorous screening for off-targets using experimental methods may be strongly encouraged before implantation of CRISPR-Cas edited cells to avoid off-target mutations resulting in malignant or ineffective transplants. Assuming these safeguards are in place, then CRISPR-Cas technologies have great potential to benefit countless patients with inherited retinal dystrophies.

Acknowledgments

Special thanks goes to Amy Caudy, Eyal Gottlieb, Adam Rosebrock for their consultations during the metabolomics course at Cold Spring Harbor Laboratory.

Financial support and sponsorship

The Jonas Children's Vision Project and Bernard & Shirlee Brown Glaucoma Laboratory, are supported by the National Institute of Health [5P30EY019007, R01EY018213, R01EY024698, 1R01EY026682, R21AG050437].

National Cancer Institute Core [5P30CA013696], the Research to Prevent Blindness (RPB) Physician-Scientist Award, unrestricted funds from RPB, New York, NY, USA. T.C. is supported by the ICO-Retina Research Foundation Helmerich Fellowships, it is sponsored by the Retina Research Foundation in cooperation with the ICOFoundation (International Council of Ophthalmology). J.D.S is supported by the RPB medical student fellowship. S.H.T. is a member of the RD-CURE Consortium and is supported by the Tistou and Charlotte Kerstan Foundation, the Schneeweiss Stem Cell Fund, New York State [C029572], the Foundation Fighting Blindness New York Regional Research Center Grant [C-NY05-0705-0312], and the Gebroe Family Foundation

References

- Scanga HL, Nischal KK. Genetics and Ocular Disorders: A Focused Review. *Pediatr Clin North Am*. 2014 Jun; 61(3):555–65. [PubMed: 24852152]
- Graw J. The genetic and molecular basis of congenital eye defects. *Nat Rev Genet*. 2003 Nov; 4(11):876–88. [PubMed: 14634635]
- Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The Sequence of the Human Genome. *Science*. 2001 Feb 16; 291(5507):1304–51. [PubMed: 11181995]
- Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. *Nature*. 2001 Feb 15; 409(6822):860–921. [PubMed: 11237011]
- Guttmacher AE, Collins FS. Welcome to the Genomic Era. *N Engl J Med*. 2003 Sep 4; 349(10):996–8. [PubMed: 12954750]
- Barrangou R, Doudna JA. Applications of CRISPR technologies in research and beyond. *Nat Biotechnol*. 2016 Sep.8:933–41.
- Govindan G, Ramalingam S. Programmable Site-Specific Nucleases for Targeted Genome Engineering in Higher Eukaryotes. *J Cell Physiol*. 2016 Nov 1; 231(11):2380–92. [PubMed: 26945523]
- Symington LS, Gautier J. Double-Strand Break End Resection and Repair Pathway Choice. *Annu Rev Genet*. 2011; 45(1):247–71. [PubMed: 21910633]
- Yanik, M., Müller, B., Song, F., Gall, J., Wagner, F., Wende, W., et al. In vivo genome editing as a potential treatment strategy for inherited retinal dystrophies. *Prog Retin Eye Res*. [Internet]. [cited 2016 Oct 7]; Available from: <http://www.sciencedirect.com/science/article/pii/S1350946216300441>
- Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier EA. Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity. *Science*. 2012 Aug 17; 337(6096):816–21. [PubMed: 22745249]
- Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-Guided Human Genome Engineering via Cas9. *Science*. 2013 Feb 15; 339(6121):823–6. [PubMed: 23287722]
- Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex Genome Engineering Using CRISPR/Cas Systems. *Science*. 2013 Feb 15; 339(6121):819–23. [PubMed: 23287718]
- Friedland AE, Tzur YB, Esvelt KM, Colaiácovo MP, Church GM, Calarco JA. Heritable genome editing in *C. elegans* via a CRISPR-Cas9 system. *Nat Methods*. 2013 Aug; 10(8):741–3. [PubMed: 23817069]
- Gratz SJ, Cummings AM, Nguyen JN, Hamm DC, Donohue LK, Harrison MM, et al. Genome Engineering of *Drosophila* with the CRISPR RNA-Guided Cas9 Nuclease. *Genetics*. 2013 Aug; 194(4):1029–35. [PubMed: 23709638]
- Yang H, Wang H, Shivalila CS, Cheng AW, Shi L, Jaenisch R. One-Step Generation of Mice Carrying Reporter and Conditional Alleles by CRISPR/Cas-Mediated Genome Engineering. *Cell*. 2013 Sep 12; 154(6):1370–9. [PubMed: 23992847]
- Jiang W, Zhou H, Bi H, Fromm M, Yang B, Weeks DP. Demonstration of CRISPR/Cas9/sgRNA-mediated targeted gene modification in *Arabidopsis*, tobacco, sorghum and rice. *Nucleic Acids Res*. 2013 Nov.41(20):e188. [PubMed: 23999092]
- DiCarlo JE, Norville JE, Mali P, Rios X, Aach J, Church GM. Genome engineering in *Saccharomyces cerevisiae* using CRISPR-Cas systems. *Nucleic Acids Res*. 2013 Apr; 41(7):4336–43. [PubMed: 23460208]
- Guo X, Li XJ. Targeted genome editing in primate embryos. *Cell Res*. 2015 Jul; 25(7):767–8. [PubMed: 26032266]

19. Flowers GP, Timberlake AT, Mclean KC, Monaghan JR, Crews CM. Highly efficient targeted mutagenesis in axolotl using Cas9 RNA-guided nuclease. *Dev Camb Engl*. 2014 May; 141(10): 2165–71.
20. Chang N, Sun C, Gao L, Zhu D, Xu X, Zhu X, et al. Genome editing with RNA-guided Cas9 nuclease in Zebrafish embryos. *Cell Res*. 2013 Apr; 23(4):465–72. [PubMed: 23528705]
21. Deltcheva E, Chylinski K, Sharma CM, Gonzales K, Chao Y, Pirzada ZA, et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. *Nature*. 2011 Mar 31; 471(7340):602–7. [PubMed: 21455174]
22. Garneau JE, Dupuis M-È, Villion M, Romero DA, Barrangou R, Boyaval P, et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. *Nature*. 2010 Nov 4; 468(7320):67–71. [PubMed: 21048762]
23. Zhang, Y., Ge, X., Yang, F., Zhang, L., Zheng, J., Tan, X., et al. Comparison of non-canonical PAMs for CRISPR/Cas9-mediated DNA cleavage in human cells; *Sci Rep* [Internet]. 2014 Jun. p. 23[cited 2016 Oct 7];4. Available from: <http://www.nature.com/articles/srep05405>
24. Jinek M, Jiang F, Taylor DW, Sternberg SH, Kaya E, Ma E, et al. Structures of Cas9 Endonucleases Reveal RNA-Mediated Conformational Activation. *Science*. 2014 Mar 14;343(6176):1247997. [PubMed: 24505130]
25. Sternberg SH, Redding S, Jinek M, Greene EC, Doudna JA. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. *Nature*. 2014 Mar 6; 507(7490):62–7. [PubMed: 24476820]
26. Mali P, Aach J, Stranges PB, Esvelt KM, Moosburner M, Kosuri S, et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. *Nat Biotechnol*. 2013 Sep; 31(9):833–8. [PubMed: 23907171]
27. Ran FA, Hsu PD, Lin C-Y, Gootenberg JS, Konermann S, Trevino AE, et al. Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity. *Cell*. 2013 Sep 12; 154(6): 1380–9. [PubMed: 23992846]
28. Hilton IB, D'Ippolito AM, Vockley CM, Thakore PI, Crawford GE, Reddy TE, et al. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. *Nat Biotechnol*. 2015 May; 33(5):510–7. [PubMed: 25849900]
29. Chavez A, Scheiman J, Vora S, Pruitt BW, Tuttle M, Iyer EPR, et al. Highly efficient Cas9-mediated transcriptional programming. *Nat Methods*. 2015 Apr; 12(4):326–8. [PubMed: 25730490]
30. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, et al. Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression. *Cell*. 2013 Feb 28; 152(5):1173–83. [PubMed: 23452860]
31. Kiani S, Chavez A, Tuttle M, Hall RN, Chari R, Ter-Ovanesyan D, et al. Cas9 gRNA engineering for genome editing, activation and repression. *Nat Methods*. 2015 Nov; 12(11):1051–4. [PubMed: 26344044]
32. Vojta A, Dobrini P, Tadi V, Bo kor L, Kora P, Julg B, et al. Repurposing the CRISPR-Cas9 system for targeted DNA methylation. *Nucleic Acids Res*. 2016 Mar.11: gkw159.
33. Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. *Nature*. 2016 May 19; 533(7603):420–4. [PubMed: 27096365]
34. Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. *Nat Biotechnol*. 2013 Sep; 31(9): 822–6. [PubMed: 23792628]
35. Tsai SQ, Zheng Z, Nguyen NT, Liebers M, Topkar VV, Thapar V, et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. *Nat Biotechnol*. 2015 Feb; 33(2):187–97. [PubMed: 25513782]
36. Peng Y, Clark KJ, Campbell JM, Panetta MR, Guo Y, Ekker SC. Making designer mutants in model organisms. *Development*. 2014 Nov 1; 141(21):4042–54. [PubMed: 25336735]
- 37 *. Wu W-H, Tsai Y-T, Justus S, Lee T-T, Zhang L, Lin C-S, et al. CRISPR Repair Reveals Causative Mutation in a Preclinical Model of Retinitis Pigmentosa. *Mol Ther*. 2016 Aug; 24(8): 1388–94. This study used precise CRISPR-Cas genome surgery to untangle the causative allele in

an commonly used preclinical model for retinitis pigmentosa, exemplifying it's use in improving animal models. [PubMed: 27203441]

38. Keeler CE. THE GEOTROPIC REACTION OF RODLESS MICE IN LIGHT AND IN DARKNESS. *J Gen Physiol.* 1928 Mar 20; 11(4):361–8. [PubMed: 19872404]
39. McLaughlin ME, Ehrhart TL, Berson EL, Dryja TP. Mutation spectrum of the gene encoding the beta subunit of rod phosphodiesterase among patients with autosomal recessive retinitis pigmentosa. *Proc Natl Acad Sci U S A.* 1995 Apr 11; 92(8):3249–53. [PubMed: 7724547]
- 40 **. Zhong H, Chen Y, Li Y, Chen R, Mardon G. CRISPR-engineered mosaicism rapidly reveals that loss of Kcnj13 function in mice mimics human disease phenotypes. *Sci Rep.* 2015 Feb 10;5:8366. By using the mutagenic effect of non-templated repair of a DSB, this project examined used CRISPR-Cas induced mosaicism at the Kcnj13 locus in adult mice and the effect on photoreceptor loss. This study exemplifies the use of CRISPR-Cas to avoid the need of constructing Cre-loxP animal lines, hence saving time. [PubMed: 25666713]
41. Stricklett PK, Nelson RD, Kohan DE. The Cre/loxP system and gene targeting in the kidney. *Am J Physiol.* 1999 May; 276(5 Pt 2):F651–7. [PubMed: 10330046]
42. Yen S-T, Zhang M, Deng JM, Usman SJ, Smith CN, Parker-Thornburg J, et al. Somatic mosaicism and allele complexity induced by CRISPR/Cas9 RNA injections in mouse zygotes. *Dev Biol.* 2014 Sep 1; 393(1):3–9. [PubMed: 24984260]
- 43 *. Duan Y, Ma G, Huang X, D'Amore PA, Zhang F, Lei H. The Clustered, Regularly Interspaced, Short Palindromic Repeats-associated Endonuclease 9 (CRISPR/Cas9)-created MDM2 T309G Mutation Enhances Vitreous-induced Expression of MDM2 and Proliferation and Survival of Cells. *J Biol Chem.* 2016 Jul 29; 291(31):16339–47. This paper shows the use of CRISPR-Cas genome surgery to a validate potentially pathogenic SNP, process that will become increasingly important in verifying unique disease causing mutations in the age of personalized precision medicine. [PubMed: 27246850]
44. Sánchez-Rivera FJ, Jacks T. Applications of the CRISPR-Cas9 system in cancer biology. *Nat Rev Cancer.* 2015 Jul; 15(7):387–95. [PubMed: 26040603]
45. Soldner F, Stelzer Y, Shivalila CS, Abraham BJ, Latourelle JC, Barrasa MI, et al. Parkinson-associated risk variant in distal enhancer of α -synuclein modulates target gene expression. *Nature.* 2016 May 5; 533(7601):95–9. [PubMed: 27096366]
46. Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. *Cell.* 2009 Feb 20; 136(4):642–55. [PubMed: 19239886]
47. Wilson RC, Doudna JA. Molecular Mechanisms of RNA Interference. *Annu Rev Biophys.* 2013; 42(1):217–39. [PubMed: 23654304]
48. Priglinger CS, Obermann J, Szober CM, Merl-Pham J, Ohmayer U, Behler J, et al. Epithelial-to-Mesenchymal Transition of RPE Cells In Vitro Confers Increased β 1,6- N -Glycosylation and Increased Susceptibility to Galectin-3 Binding. *PLOS ONE.* 2016 Jan 13;11(1):e0146887. [PubMed: 26760037]
49. Lee JJ, Park JK, Kim Y-T, Kwon B-M, Kang SG, Yoo YD, et al. Effect of 2'-Benzoyl-oxy-cinnamaldehyde on RPE Cells In Vitro and in an Experimental Proliferative Vitreoretinopathy Model. *Invest Ophthalmol Vis Sci.* 2002 Sep 1; 43(9):3117–24. [PubMed: 12202537]
50. Richardson, R., Tracey-White, D., Webster, A., Moosajee, M. The zebrafish eye—a paradigm for investigating human ocular genetics. *Eye* [Internet]. 2016 Sep 9. [cited 2016 Oct 8]; Available from: <http://www.nature.com/eye/journal/vaop/ncurrent/full/eye2016198a.html>
51. Yin L, Maddison LA, Li M, Kara N, LaFave MC, Varshney GK, et al. Multiplex Conditional Mutagenesis Using Transgenic Expression of Cas9 and sgRNAs. *Genetics.* 2015 Jun 1; 200(2): 431–41. [PubMed: 25855067]
52. Ramachandran R, Fausett BV, Goldman D. Ascl1a regulates Muller glia dedifferentiation and retinal regeneration through a Lin-28-dependent, let-7 microRNA signalling pathway. *Nat Cell Biol.* 2010 Nov; 12(11):1101–7. [PubMed: 20935637]
53. Taylor SM, Alvarez-Delfin K, Saade CJ, Thomas JL, Thummel R, Fadool JM, et al. The bHLH Transcription Factor NeuroD Governs Photoreceptor Genesis and Regeneration Through Delta-Notch Signaling. *Invest Ophthalmol Vis Sci.* 2015 Nov; 56(12):7496–515. [PubMed: 26580854]

54. Liu X, Homma A, Sayadi J, Yang S, Ohashi J, Takumi T. Sequence features associated with the cleavage efficiency of CRISPR/Cas9 system. *Sci Rep*. 2016 Jan 27;6:19675. [PubMed: 26813419]
55. Courtney DG, Moore JE, Atkinson SD, Maurizi E, Allen EHA, Pedrioli DML, et al. CRISPR/Cas9 DNA cleavage at SNP-derived PAM enables both in vitro and in vivo KRT12 mutation-specific targeting. *Gene Ther*. 2016 Jan; 23(1):108–12. [PubMed: 26289666]
- 56 **. Bakondi B, Lv W, Lu B, Jones MK, Tsai Y, Kim KJ, et al. In Vivo CRISPR/Cas9 Gene Editing Corrects Retinal Dystrophy in the S334ter-3 Rat Model of Autosomal Dominant Retinitis Pigmentosa. *Mol Ther*. 2016 Mar; 24(3):556–63. This study demonstrates the power of using CRISPR-Cas to introduce NHEJ into a dominant negative allele in vivo as well as quantifies the therapeutic result with behavioral assays. [PubMed: 26666451]
- 57 *. Hung SSC, Chrysostomou V, Li F, Lim JKH, Wang J-H, Powell JE, et al. AAV-Mediated CRISPR/Cas Gene Editing of Retinal Cells In Vivo. *Investig Ophthalmology Vis Sci*. 2016 Jun 29;57(7):3470. In vivo editing of retinal and other eye tissue in a clinical setting will likely increase in frequency. Using a fluorescent gene target integrated in a genomic locus, this study quantified the transduction and cutting/mutagenic capacity of CRISPR-Cas elements delivered by AAV vector in a mouse model.
58. Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ, et al. In vivo genome editing using *Staphylococcus aureus* Cas9. *Nature*. 2015 Apr 9; 520(7546):186–91. [PubMed: 25830891]
59. Swiech L, Heidenreich M, Banerjee A, Habib N, Li Y, Trombetta J, et al. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. *Nat Biotechnol*. 2015 Jan; 33(1):102–6. [PubMed: 25326897]
60. Yang Y, Wang L, Bell P, McMenamin D, He Z, White J, et al. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. *Nat Biotechnol*. 2016 Mar; 34(3):334–8. [PubMed: 26829317]
61. Long C, Amoasii L, Mireault AA, McAnally JR, Li H, Sanchez-Ortiz E, et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. *Science*. 2016 Jan 22; 351(6271):400–3. [PubMed: 26721683]
62. Tabebordbar M, Zhu K, Cheng JKW, Chew WL, Widrick JJ, Yan WX, et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. *Science*. 2016 Jan 22; 351(6271):407–11. [PubMed: 26721686]
63. Chew WL, Tabebordbar M, Cheng JKW, Mali P, Wu EY, Ng AHM, et al. A multifunctional AAV-CRISPR-Cas9 and its host response. *Nat Methods*. 2016 Oct; 13(10):868–74. [PubMed: 27595405]
64. Brenner M. The Eyes Have It. *Mol Ther*. 2010 Mar; 18(3):451–2. [PubMed: 20195259]
65. Willett, K., Bennett, J. Immunology of AAV-Mediated Gene Transfer in the Eye; *Front Immunol* [Internet]. 2013 Aug. p. 30[cited 2016 Oct 4];4. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757345/>
66. Vandenberghe LH. What Is Next for Retinal Gene Therapy? *Cold Spring Harb Perspect Med*. 2015 Oct 1;5(10):a017442. [PubMed: 25877395]
67. Li, Y., Nguyen, H., Tsang, S. Skin Biopsy and Patient-Specific Stem Cell Lines. In: Nagy, A., Turksen, K., editors. *Patient-Specific Induced Pluripotent Stem Cell Models* [Internet]. Springer; New York: 2016. [cited 2016 Oct 10]. p. 77–88 (Methods in Molecular Biology). Available from: http://dx.doi.org/10.1007/7651_2015_225
68. Li, Y., Chan, L., Nguyen, HV., Tsang, SH. Personalized Medicine: Cell and Gene Therapy Based on Patient-Specific iPSC-Derived Retinal Pigment Epithelium Cells. In: Rickman, CB, LaVail, MM, Anderson, RE, Grimm, C, Hollyfield, J., Ash, J., editors. *Retinal Degenerative Diseases* [Internet]. Springer International Publishing; 2016. [cited 2016 Oct 10]. p. 549–55 (Advances in Experimental Medicine and Biology). Available from: http://link.springer.com/chapter/10.1007/978-3-319-17121-0_73
69. Li Y, Tsai Y-T, Hsu C-W, Erol D, Yang J, Wu W-H, et al. Long-term safety and efficacy of human-induced pluripotent stem cell (iPS) grafts in a preclinical model of retinitis pigmentosa. *Mol Med Camb Mass*. 2012; 18:1312–9. [PubMed: 22895806]

70. Li Y, Tsai Y-T, Hsu C-W, Erol D, Yang J, Wu W-H, et al. Lines and a Preclinical Model of Retinitis Pigmentosa With Membrane Frizzled-related Protein Defects. *Mol Ther*. 2014 Sep; 22(9):1688–97. [PubMed: 24895994]
71. Wang N-K, Tosi J, Kasanuki JM, Chou CL, Kong J, Parmalee N, et al. Transplantation of Reprogrammed Embryonic Stem Cells Improves Visual Function in a Mouse Model for Retinitis Pigmentosa. *Transplantation*. 2010 Apr; 89(8):911–9. [PubMed: 20164818]
- 72 **. Bassuk AG, Zheng A, Li Y, Tsang SH, Mahajan VB. Precision Medicine: Genetic Repair of Retinitis Pigmentosa in Patient-Derived Stem Cells. *Sci Rep*. 2016 Jan 27;6:19969. This study was an impressive first step at correction of a pathogenic allele in a highly repetitive locus in patient-derived iPSCs. Ex vivo gene editing and re-implantation represent important approaches for the correction of disease processes amenable to cell replacement. [PubMed: 26814166]
73. Sluch VM, Davis CO, Ranganathan V, Kerr JM, Krick K, Martin R, et al. Differentiation of human ESCs to retinal ganglion cells using a CRISPR engineered reporter cell line. *Sci Rep*. 2015 Nov 13;5:16595. [PubMed: 26563826]
74. Snapp EL. Fluorescent Proteins: A Cell Biologist's User Guide. *Trends Cell Biol*. 2009 Nov; 19(11):649–55. [PubMed: 19819147]

Key Points

- CRISPR-Cas genome surgery can make precise modifications in mammalian and non-mammalian preclinical models of eye disease and development
- Targeting autosomal dominant mutations clinically may be especially effective because the process does not require a corrected version of the gene
- Delivery of CRISPR-Cas components via AAV vectors is effective in model systems
- *Ex vivo* genome surgery to correct mutations of patient derived iPSCs and ESCs for future re-implantation is a promising therapeutic

Figure 1.

Wild-type SpCas9 (**A**) has been modified extensively to attenuate, Cas9 Nickase, (**B**) and remove its double-strand DNA cutting activity, dCas9 (**C**). It has also been modified via protein fusion to generate targeted transcriptional activators (**D**), epigenetic modifiers such as methyltransferase and acetyltransferases (**E**), and domains that allow for precise cytosine to uracil modifications in the case of deaminases (**F**)

Figure 2.

(A) Gene supplementation approaches using traditional gene delivery is useful for adding additional copies of wild-type alleles in the case of recessive negative allele genotypes, but ineffective at removing pathogenic dominant negative alleles, where the mutant allele expressed causes damaging effects. (B). CRISPR-Cas9 genome surgery has the benefit of precisely removing pathogenic alleles, regardless if they are dominant or recessive, resulting in permanently modified healthy cells.